Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib Plus EGFR-TKI in First-Line EGFR-Mutated Non-squamous NSCLC
NCT03634059Unknown
- Sponsor
- The Fourth Hospital of Hebei Medical University
- Start
- Aug 2018
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of Rivoceranib in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC), sponsored by The Fourth Hospital of Hebei Medical University. Primary endpoint: Progression free survival at 2 years. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT03634059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03634059.